# **Circulatory support**

<details class="med-details">
<summary><span style="font-size:110%">Pharmacological support</span></summary>
<div class="details-content">

There is a lack of robust clinical evidence demonstrating a positive impact on survival concerning the use of vasoactive agents. Their use is considered part of supportive care allowing time for definitive treatment of underlying disease processes. This treatment might involve antibiotics for sepsis, management of arrhythmias, or, in the context of cardiothoracic critical care, interventions such as PCI, surgical revascularization, or the institution of mechanical support (discussed in  üìñ  Mechanical circulatory support).

The selection and safe use of a particular vasoactive agent is based on knowledge of its cardiovascular effects, clinical indications, and an understanding of its clinical use.

<details class="med-details">
<summary>Inotropic agents</summary>
<div class="details-content">


<details class="med-details">
<summary>Catecholamines</summary>
<div class="details-content">

Catecholamines exert their cardiovascular effects via activity at specific adrenergic  Œ±<sub>1</sub>,Œ≤<sub>1</sub>,Œ≤<sub>2</sub>)  and dopaminergic  (D<sub>1</sub>)  receptors. Sensitive  Œ≤ receptor effects ae evident at low plasma concentrations while  Œ±  effects become more prominent at higher concentrations.

Myocardial contractility is enhanced by activity at  Œ≤<sub>1</sub>  receptors leading to  ‚Üë  levels of cAMP and intracellular  Ca<sup>2+</sup>  with the inevitable consequence of  ‚Üë  myocardial oxygen consumption (MVO<sub>2</sub>).


<details class="med-details">
<summary>Dobutamine</summary>
<div class="details-content">

- Synthetic catecholamine.
- Direct  Œ≤<sub>1</sub> > Œ≤<sub>2</sub>  agonist (3:1 ratio) with some  Œ±<sub>1</sub>  activity.


<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- ‚Üë  contractility ( Œ≤<sub>1</sub>  with  Œ±<sub>1</sub> ).
- ‚Üë HR and AV conduction (Œ≤‚ÇÅ).
- Vasodilatation ( Œ≤<sub>2</sub>  with mixed  Œ±<sub>1</sub>  agonism/antagonism) at low doses (<5mcg/kg/min).
- Variable effects on vasculature at intermediate doses.
- Vasoconstriction ( Œ±<sub>1</sub> ) at higher doses (>15mcg/kg/min).

Predominant effects are increases in SV and CO with SVR moderately reduced or unchanged. MAP may thus fall, remain unchanged, or rise with increasing CO. ‚Üë MVO<sub>2</sub> is attenuated by a reduction in preload/afterload and offset by augmented myocardial blood flow.
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- First-line agent to support borderline CO post cardiac surgery.
- Low CO (DHF, cardiogenic shock, sepsis-induced myocardial dysfunction).
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Dosing: 2.5‚Äì25mcg/kg/min; max. 40mcg/kg/min.
- Onset 2 minutes; peak effect 10 minutes; plasma half-life 2 minutes.
- Addition of a vasopressor (e.g. noradrenaline) is often required to maintain MAP.
- Increases HR more than adrenaline for similar increases in CO and may be used as indirect chronotrope.
- Tachycardia and arrhythmias limit upper dose.
- Tachyphylaxis occurs after 48‚Äì72 hours.
</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Dopamine</summary>
<div class="details-content">

- Endogenous catecholamine precursor to noradrenaline.
- Œ±<sub>1</sub> ,  Œ≤<sub>1</sub>, Œ≤<sub>2</sub> ,  D<sub>1</sub>  agonist with release of neuronal noradrenaline.


<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- ‚Üë contractility (Œ≤‚ÇÅ)
- ‚Üë HR and AV conduction (Œ≤‚ÇÅ)
- Vasodilatation at lower doses (0.5‚Äì3mcg/kg/min) Renal, mesenteric, coronary (D<sub>1</sub>), peripheral vessels (Œ≤<sub>2</sub>)
- Mild vasoconstriction ( Œ±<sub>1</sub> ) (3‚Äì10mcg/kg/min)
- Vasoconstriction ( Œ±<sub>1</sub> ) at higher doses (10‚Äì20mcg/kg/min)

Predominant effects are an increase in SV and CO with mild increases in SVR and ‚Üë MAP. Vasoconstriction at higher doses raises SVR and MAP but also increases PVR and MVO<sub>2</sub>.
</div>
</details>

<details class="med-details">
<summary>Renal effects</summary>
<div class="details-content">

- ‚Üë renal blood flow via ‚Üë CO (Œ≤‚ÇÅ) and vasodilatation (D‚ÇÅ).
- ‚Üë urine output secondary to ‚Üë renal blood flow and enhanced natriuesis (D<sub>1</sub>) without altering creatinine clearance
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- First-line agent to support borderline CO post cardiac surgery.
- Shock (cardiogenic, vasodilatory).
- Augmentation of diuresis in DHF.
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Dosing: 2‚Äì20mcg/kg/min; max. 50mcg/kg/min.
- Peak effect 5‚Äì10 minutes; plasma half-life 2 minutes.
- Plasma concentrations unpredictable due to variable clearance in the critically ill.
- Tachyarrhythmias may limit use even at lower doses.
- If inadequate response at <10mcg/kg/min consider switch to adrenaline or addition of a second agent.
- Low-dose dopamine is not effective in the prevention or treatment of acute renal failure.
</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Adrenaline</summary>
<div class="details-content">

- Endogenous catecholamine.
- Potent  Œ±<sub>1</sub> ,  Œ≤<sub>1</sub>/ Œ≤<sub>2</sub>  agonist.

<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- ‚Üë contractility  Œ≤<sub>1</sub>, Œ≤<sub>2</sub>, Œ±<sub>1</sub> .
- ‚Üë HR and AV conduction  Œ≤<sub>1</sub> .
- Vasodilatation ( Œ≤<sub>2</sub> ) at low doses (<0.03mcg/kg/min).
- Vasoconstriction  Œ±<sub>1</sub>  at higher doses (>0.03mcg/kg/min).

Increases in SV, HR, CO, and SVR result in significant increases in MAP and  MVO<sub>2</sub> . In septic shock, increases in MAP are achieved predominantly by increasing SV.
</div>
</details>


<details class="med-details">
<summary>Additional effects</summary>
<div class="details-content">

- Bronchodilation (Œ≤<sub>2</sub>).
- Mast cell stabilization.

- ‚Üë lactate levels (enhanced glycogenolysis and glycolysis with reduced pyruvate utilization).
- ‚Üë glucose levels (enhanced glycogenolysis).
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- First-line agent to support low CO post cardiac surgery.
- Shock (cardiogenic, vasodilatory).
- Bronchospasm/anaphylaxis.
- Cardiac arrest.
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Dosing: 0.01‚Äì0.5mcg/kg/min; >0.05mcg/kg/min rarely indicated following cardiac surgery.
- Greater efficacy than the other catecholamines.
- Can be used in combination with a phosphodiesterase (PDE) inhibitor to augment CO without the same increases in afterload and MVO<sub>2</sub> .
- Tachyarrhythmias remain relatively common.
</div>
</details>

</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Phosphodiesterase inhibitors</summary>
<div class="details-content">


<details class="med-details">
<summary>Milrinone and Enoximone</summary>
<div class="details-content">

‚Ä¢ Inhibit PDE breakdown of cAMP in cardiac myocytes and vascular smooth muscle.

<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- ‚Üë contractility.
- Enhanced diastolic relaxation.
- Modest increase HR and AV conduction.
- Vasodilatation.

Increases in SV and CO are achieved via moderate increases in contractility along with reduced SVR/PVR. MAP is commonly reduced. Reductions in preload/afterload have a beneficial effect on MVO<sub>2</sub> .
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- Second-line agents to support low CO post cardiac surgery.
- Low CO with raised SVR.
- Biventricular or RV failure associated with i PVR, e.g. before and after cardiac transplant, mitral valve surgery.
</div>
</details>



<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Milrinone: loading dose 25‚Äì50mcg/kg; infusion 0.375‚Äì0.75mcg/kg/min; Half-life 2‚Äì4 hours.
- Enoximone: loading dose 0.5‚Äìmg/kg; infusion 2.5‚Äì20mcg/kg/min; half-life 4‚Äì6 hours.
- Long half-life means titration to effect is achieved over hours rather than minutes and effects (beneficial and adverse) are similarly prolonged.
- Synergistic effect on CO when used with catecholamines.
- Vasodilatation, which limits clinical use, often requires the addition of a vasopressor (e.g. noradrenaline).
- Useful in the setting of adrenergic receptor downregulation, e.g. chronic HF, or after chronic Œ≤-agonist administration.
- Less tachycardia and risk of arrhythmias than with dobutamine.
</div>
</details>

</div>
</details>

</div>
</details>


<details class="med-details">
<summary>Levosimendan</summary>
<div class="details-content">

In common with other members of the calcium sensitizer class levosimendan exerts its main inotropic effects by increasing calcium binding to troponin C. It also opens ATP sensitive K<sup>+</sup> channels and inhibits PDE.

<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- ‚Üë contractility (Ca<sup>2+</sup> sensitization).
- Vasodilatation (K<sup>+</sup> channel opening).
- Enhanced diastolic relaxation (PDE inhibitor activity).

Overall effects are similar to those of PDE inhibitors with increases in SV and CO and a reduction in SVR/PVR. MAP is reduced or unchanged. Minimal effect on MVO<sub>2</sub> while coronary blood flow is ‚Üë.
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- Currently third-line agent to support CO post cardiac surgery.
- Low CO (cardiogenic shock, DHF).
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Loading dose 6‚Äì12mcg/kg; infusion 0.05‚Äì0.2mcg/kg/min for 24 hours.
- Active metabolites; effects persist for up to 9 days.
- May also be useful in adrenergic receptor downregulation.
- When compared with dobutamine it provides similar improvements in CO with smaller increases in MVO<sub>2</sub>.
- Some evidence to suggest improved outcomes in cardiac surgery.
- No long-term survival benefit over dobutamine in treatment of acute DHF.
- Potential for QT prolongation and ventricular arrhythmias.
</div>
</details>

</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Vasopressors</summary>
<div class="details-content">

<details class="med-details">
<summary>Noradrenaline</summary>
<div class="details-content">
  
- Endogenous catecholamine.
- Potent  Œ±<sub>1</sub>  agonist; modest   Œ≤<sub>1</sub>  and limited   Œ≤<sub>2</sub>  activity.

<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- Vasoconstriction  Œ±<sub>1</sub>  characterizes its clinical effect.
- Modest increases in contractility  Œ≤<sub>1</sub> .
- Minimal increase in HR  Œ≤<sub>1</sub> , or reflex decrease  Œ±<sub>1</sub>.
- Increases PVR

Increases in SVR, with modest increases in SV result in elevated systolic, diastolic and pulse pressure with minimal impact on CO.  ‚Üë  afterload and contractility result in  ‚Üë  MVO<sub>2</sub> though coronary flow is  ‚Üë  secondary to elevated diastolic BP.
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

Shock (vasodilatory).
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Dosing: 0.01‚Äì0.3mcg/kg/min; titrated according to MAP or SVR.
- Can be used alone if CO is satisfactory or in combination with an inotrope (e.g. dobutamine/milrinone) if CO is compromised.
- Risk of arterial conduit vasospasm and a reduction in renal/splanchnic blood flow particularly at higher doses.
</div>
</details>

</div>
</details>



<details class="med-details">
<summary>Vasopressin</summary>
<div class="details-content">

- Endogenous peptide hormone.
- Activity at V1, V2, V3, and oxytocin-type receptors (OTR).

<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- Vasoconstriction (V1) characterizes its clinical effect.
- Relative sparing of pulmonary, coronary, and cerebral circulations.

Splanchnic, skeletal muscle, and cutaneous vessels are particularly affected. Impact on CO is dependent on increases in SVR and reflex changes in HR.
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

‚Ä¢ Shock (vasodilatory, e.g. vasoplegic syndrome).
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Dosing: 0.01‚Äì0.1U/min; commonly 0.04U/min.
- Effects relatively preserved during hypoxia and acidosis.
- Reduces splanchnic blood flow more than noradrenaline and may precipitate myocardial ischaemia at higher doses.
- Often introduced in the context of escalating noradrenaline requirements.
  Maintains vascular tone when noradrenaline sensitivity is reduced.
</div>
</details>

</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Vasodilators</summary>
<div class="details-content">

<details class="med-details">
<summary>Glyceryl trinitrate</summary>
<div class="details-content">

‚Ä¢ Vascular smooth muscle relaxation via ‚Üë cGMP production.

<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- Vasodilatation (venous > arterial)
- ‚Üì preload results in a fall in CO, MVO<sub>2</sub>, and a modest reduction in MAP.
  Higher dosing results in a fall in SVR and MAP.
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- Hypertension.
- Acute DHF with pulmonary oedema.
- Myocardial ischaemia.
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Dosing: 1‚Äì10mg/hour; titrated upwards according to MAP.
- Although potentially beneficial in the treatment of pulmonary hypertension its use is limited by falls in SVR/MAP.
- Beneficial effects on myocardial ischaemia are primarily due to reductions in MVO<sub>2</sub> rather than coronary vasodilatation.
- Tachyphylaxis may occur with prolonged infusion.
</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Sodium nitroprusside</summary>
<div class="details-content">

Smooth muscle relaxation via release of nitric oxide, increasing cGMP.

<details class="med-details">
<summary>Dose-dependent CVS effects</summary>
<div class="details-content">

- Vasodilatation (arterial and venous).
- SVR is reduced. CO is maintained or ‚Üë.
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- Hypertension secondary to ‚Üë SVR.
- Acute DHF.
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Dosing: 0.1‚Äì2mcg/kg/min; titrated according to MAP.
- Commonly added to GTN for treatment of resistant hypertension.
- Potential for rebound increases in SVR/MAP on withdrawal.
- Cyanide toxicity is dose and duration dependent and results in tissue hypoxia despite an adequate PaO<sub>2</sub>.
</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Inhaled nitric oxide</summary>
<div class="details-content">

Vascular smooth muscle relaxation via ‚Üë cGMP.

<details class="med-details">
<summary>Dose-dependent effects</summary>
<div class="details-content">

- Pulmonary vasodilatation.
- Reduced PVR/RV afterload and improved V/Q matching. Rapidly inactivated by haemoglobin minimizing systemic effects.
</div>
</details>

<details class="med-details">
<summary>Clinical indications</summary>
<div class="details-content">

- Pulmonary hypertension and/or RV dysfunction with potential reversibility, e.g. following cardiac transplant, mitral valve surgery.
- ARDS with refractive hypoxaemia.
</div>
</details>

<details class="med-details">
<summary>Clinical use</summary>
<div class="details-content">

- Initial dose: 20ppm, with subsequent reduction to achieve minimum effective dose (usually 1‚Äì5ppm).
- Titrated according to pulmonary artery pressure measurements.
- Administered via inspiratory limb of a primed ventilator circuit to minimize nitrogen dioxide levels
- Potential for rebound pulmonary hypertension when weaning dose; sildenafil can be used as an adjunct to withdrawal.
- Improvements in PaO<sub>2</sub>, in ARDS are not sustained.
- No studies have shown that its use reduces mortality.
</div>
</details>

</div>
</details>

</div>
</details>


</div>
</details>


<details class="med-details">
<summary><span style="font-size:110%">Mechanical circulatory support: extracorporeal life support</span></summary>
<div class="details-content">

Mechanical support of the circulation can be lifesaving. Intra-aortic balloon pump (IABP) counterpulsation has long been used as an effective form of circulatory support post cardiotomy; however, it has limitations in advanced circulatory failure. The IABP's main mechanism of action is augmentation of the diastolic myocardial perfusion pressure and reduction in afterload. The improvement in cardiac function often allows weaning of inotropes and the avoidance of harm from their deleterious effects. IABP may be ineffective if cardiac function is profoundly impaired and has the disadvantage that the patient is confined to bed. Short-term ventricular assist devices (VADS) provide full circulatory support which can bridge the patient to either recovery, decision, or transplantation. Where recovery or transplantation is not anticipated in a period of 28 days but is likely to occur, a long-term VAD may be used. Extracorporeal membrane oxygenation (ECMO) may be used for cardiorespiratory support and has a place in the management of both children and adults. The indications, contraindications, and management of these devices are considered in this section.


<details class="med-details">
<summary>Intra-aortic balloon pump counterpulsation</summary>
<div class="details-content">

IABPs inflate in diastole which augments the diastolic pressure and improves myocardial oxygen supply, deflation on the R wave immediately before systole decreases afterload, and myocardial oxygen demand (Figs 27.1 and 27.2). The improvement in this supply-demand balance improves ischaemic myocardial failure and systemic perfusion.


<details class="med-details">
<summary>Indications</summary>
<div class="details-content">
The commonly used indications for an IABP are:

- Myocardial 'stunning' after cardiac surgery
- Refractory unstable angina awaiting CABG
- Refractory ischaemic ventricular arrhythmias
- The complications of acute MI:
  - ‚Ä¢ Acute severe mitral regurgitation
  - ‚Ä¢ Ventricular septal defect (VSD) ‚Ä¢ The unstable primary PCI patient
- Refractory ventricular failure.
</div>
</details>

<details class="med-details">
<summary>Contraindications</summary>
<div class="details-content">

- Severe aortic regurgitation
- Severe calcific aorto-iliac disease and/or peripheral vascular disease
- Disease of the descending aorta (aortic coarctation or aneurysm)
- Sheathless insertion in severe obesity.
</div>
</details>

<details class="med-details">
<summary>Potential risks and complications</summary>
<div class="details-content">

- Ischaemic limb
- Bleeding from the insertion site
- Aorta perforation or dissection
- Retroperitoneal bleeding
- Patient confined to bed and <45¬∞ head up
- Infection risk particularly with femoral cannulation

- Limb ischaemia
- Thrombocytopenia
- Balloon leak
- Compartment syndrome.
</div>
</details>


![](_page_8_Figure_6.jpeg)

Figure 27.1 IABP pressure tracing showing diastolic augmentation. Courtesy of MAQUET Cardiac Assist Division.

![](_page_8_Picture_9.jpeg)

Figure 27.2 Diagram demonstrating an IABP *in situ*. Courtesy of MAQUET Cardiac Assist Division.
</div>
</details>

<details class="med-details">
<summary>Short-term ventricular assist devices</summary>
<div class="details-content">

Short-term VADs are used to support a failing circulation for up to 28 days. The commonest device in use currently in the UK is the Levotronix CentriMag¬Æ (Fig. 27.3) which is licensed for 28 days. The CentriMag¬Æ is a centrifugal blood pump based on bearingless motor design, magnetic forces are generated to levitate and spin the rotors which propel the blood producing non pulsatile flow.

Short-term VADs have increasingly been used in CICUs as a means to support a failing circulation until recovery has occurred or more definitive treatment can be instituted (Fig. 27.4).

The circuit and pump is designed to minimize risks of clot formation and embolic complications. Despite this anticoagulation with unfractionated heparin is required which must be carefully monitored by frequent activated partial thromboplastin times (APTTs).

<details class="med-details">
<summary>Treatment strategy</summary>
<div class="details-content">

- Bridge to decision
- Bridge to recovery
- Bridge to bridge (long-term device)
- Bridge to transplantation.
</div>
</details>

<details class="med-details">
<summary>Indications</summary>
<div class="details-content">

- Dilated cardiomyopathy:
  - ‚Ä¢ Ischaemic
  - ‚Ä¢ Myocarditis
  - ‚Ä¢ Peripartum
- Post cardiotomy
- Congenital heart disease
- Primary graft failure post cardiac transplantation.
</div>
</details>

<details class="med-details">
<summary>Characteristics of the Levotronix CentriMag¬Æ</summary>
<div class="details-content">

![](_page_9_Picture_19.jpeg)

Figure 27.3 The Levitronix CentriMag¬Æ. Reprinted with the permission of Thoratec Corporation.
  

- Flows up to 9.9L/min
- No seals or bearings, one moving part
- Magnetically levitated impeller
- Licensed for 30 days
- Cost-effective
- Mobility limited.
</div>
</details>

<details class="med-details">
<summary>Different treatment modalities</summary>
<div class="details-content">

- Left VAD
- Right VAD
- Bi-VAD
- ECMO.
</div>
</details>


![](_page_10_Picture_14.jpeg)

Figure 27.4 A patient with a short-term ventricular assist device. 

<details class="med-details">
<summary>Cannulation options</summary>
<div class="details-content">

#### *LVAD*

- Inflow cannula:
  - ‚Ä¢ Left atrium (via right upper pulmonary vein)
  - ‚Ä¢ Ventricular apex
- Outflow cannula:
  - ‚Ä¢ Ascending aorta
   - ‚Ä¢ Descending aorta.

#### *RVAD*

- Outflow cannula from right atrium
- Inflow cannula to pulmonary artery.
</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Long-term ventricular assist devices</summary>
<div class="details-content">

The main indication for long-term VADs in the UK is bridge to transplantation. Worldwide as the survival on VADs has improved, the use of long-term VADs for destination therapy has ‚Üë.

<details class="med-details">
<summary>Indications</summary>
<div class="details-content">

- Bridge to transplant
- Bridge to recovery.
</div>
</details>

<details class="med-details">
<summary>Types of long VADS</summary>
<div class="details-content">

- 1st generation: pulsatile displacement pumps
- 2nd generation; continuous flow by rotating impellers
- 3rd generation: centrifugal miniaturized to size of D battery.

![](_page_11_Picture_11.jpeg)

Figure 27.5 The Thoratec HeartMate II¬Æ. 
</div>
</details>

<details class="med-details">
<summary>Components of a long-term LVAD</summary>
<div class="details-content">

- Battery pack
- Mains power module when not mobilizing
- Drive line
- Pump
- Inflow cannula from LV apex to pump
- Outflow cannula form pump usually to ascending aorta.
</div>
</details>

<details class="med-details">
<summary>Clinical issues of a long-term LVAD</summary>
<div class="details-content">

- Requires functioning RV
- Anticoagulation with warfarin to INR 1.5‚Äì2.5
- Battery life 4 hours
- Mobilization possible
- Home discharge is the norm
- Resuscitation:
  - ‚Ä¢ No CPR
  - ‚Ä¢ *Always defibrillate a shockable rhythm*
- Complicates surgical procedure for heart transplantation.
</div>
</details>

<details class="med-details">
<summary>Complications in the early postoperative period in ICU</summary>
<div class="details-content">

- Bleeding can be a major problem:
  - ‚Ä¢ The causes are surgical, liver dysfunction, residual anticoagulation, and inflammatory-induced coagulopathy and platelet dysfunction.

- ‚Ä¢ Early intervention to stop haemorrhage is important.
- ‚Ä¢ Surgical reopening is common.
- ‚Ä¢ Anticoagulation should be restarted cautiously once bleeding is controlled.
- Right heart failure:
  - ‚Ä¢ May be due to RV myocardial dysfunction, ventricular interdependence, and i afterload.
  - ‚Ä¢ Excessive blood product administration may elevate the PVR and increase RV overload.
  - ‚Ä¢ RV may be impaired due to underlying aetiology of heart failure.
  - ‚Ä¢ Short-term RVAD hay be required.
  - ‚Ä¢ RV failure may contribute to the 'suck down effect' where the walls of the left ventricle collapse onto the outflow cannula.
- Hypovolaemia may result in poor pump flow due to lack of venous return.
- Respiratory failure.
- Hepto-renal dysfunction.
</div>
</details>

<details class="med-details">
<summary>Long-term complications</summary>
<div class="details-content">

The survival at 2 years of patients who were NYHA IIIb or IV and ineligible for transplantation and treated with a continuous flow pump for destination therapy was 58% at 2 years. Complications were common and tended to be infection, bleeding or thromboembolic related.

- Stroke 18%:
  - ‚Ä¢ Ischaemic
  - ‚Ä¢ Haemorrhagic
- Sepsis 36%:
  - ‚Ä¢ Drive line infection
  - ‚Ä¢ Pump and pocket infection
  - ‚Ä¢ Non-LVAD infection
- Pump replacement 9%
- Right heat failure 20%
- Renal and hepatic failure.
</div>
</details>

</div>
</details>

<details class="med-details">
<summary>ECMO</summary>
<div class="details-content">

Extracorporeal life support can be used for cardiorespiratory support (veno-arterial (V-A) ECMO) or respiratory support (veno-venous (V-V) ECMO). In the circuit, generally centrifugal pumps have replaced roller pumps. Compared to CPB, in ECMO a membrane oxygenator designed for long-lasting use is inserted into the circuit. The circuit is simplified to minimize the risk of clotting and inflammatory activation so there is no cardiotomy reservoir.

<details class="med-details">
<summary>V-A ECMO</summary>
<div class="details-content">

V-A ECMO can be used as 'crash and burn' resuscitative option in patients with acute cardiogenic shock. The technique allows assessment of neurological function and the potential for end-organ recovery prior to embarking on a long-term VAD. It is commonly used in paediatric cardiac surgery for post cardiotomy failure.

- Can be introduced open or percutaneously.
- Femoral arterial cannulation is popular for percutaneous option.

- Venous cannulation is achieved directly from the right atrium or percutaneously via the right internal jugular or femoral veins.

<details class="med-details">
<summary>Risks and complications</summary>
<div class="details-content">

- Air embolism
- Bleeding
- Thrombotic risk
- Stroke
- Ischaemic limbs
- Haemolysis
- Infection
- Immobility.
</div>
</details>

</div>
</details>

<details class="med-details">
<summary>V-V ECMO</summary>
<div class="details-content">

V-V ECMO is used to allow resting of the lungs in patients with severe respiratory failure. It has been used mainly in neonatal and paediatrics. The duration of support is usually 1‚Äì2 weeks.

RDS in the adult population has a mortality in excess of 50%. The CESAR study has demonstrated benefits from specialist ECMO centres in the management of these patients.

Cannulation is by percutaneous cannulation of a major vein (internal jugular and/or femoral) with fluoroscopic (or TOE) guidance. Recent bicaval two-stage cannula (Avalon cannula) can be introduced via the IJV.

The indications and outcomes of ECMO are collected by the ELSO registry. In adults, survival with respiratory V-V ECMO support are better than cardiac V-A ECMO at 55% vs 39% at discharge.
###### Table 27.1 ECLS Registry report
||| Total Patients || Survived ECLS ||| Survived to DC or Transfer ||
|-|-|-|-|-|-|-|-|-|
| <strong>Neonatal</strong> |||||||||
| Respiratory || 24,770 || 20,951 | 85% || 18,558   | 75% |
| Cardiac || 4,375 || 2,649 | 61% || 1,723 | 39% |
| ECPR || 694 || 438 | 63% || 270 | 39% |
| <strong>Pediatric</strong> ||||||
| Respiratory || 5,009 || 3,251 | 65% || 2,785 | 56% |
| Cardiac || 5,423 || 3,468 | 64% ||2,609 | 48% |
| ECPR || 1,347 || 720 | 53% || 539 | 40% |
| <strong>Adult</strong> |||||||||
| Respiratory ||2,620 || 1,655 | 63% || 1,428 | 55% |
| Cardiac || 1,680 || 894 | 53% || 660 | 39% |
| ECPR || 591 || 225 | 38% || 173 | 29% |
| <strong>Total</strong> || 46,509 || 34,251| 74% ||28,745  | 62% |

<details class="med-details">
<summary>Respiratory aetiology of patients treated with ECMO</summary>
<div class="details-content">

- Meconium aspiration in neonates
- Viral pneumonitis including influenza and H1N1
- Other pneumonias
- Respiratory distress syndrome
- Trauma including postoperative.
</div>
</details>

<details class="med-details">
<summary>Indications for adult ECMO in the CESAR study</summary>
<div class="details-content">

- Age 18‚Äì65 years
- Severe respiratory failure but potentially reversible
- Failed conventional management
- Murray score >3.0 or pH < 7.2
- Early referral <7 days with peak inspiratory pressure >30cmH<sub>2</sub>O and FiO<sub>2</sub> >0.8.
- No contraindication to heparin.
</div>
</details>

<details class="med-details">
<summary>Circuit requirements</summary>
<div class="details-content">

- Suitable PMP oxygenators include the Maquet Quadrox D<sup>¬Æ</sup> and the Medos Hi-Lite<sup>¬Æ</sup> 7000.
- Centrifugal pump, ideally of modern design such as the Levitronix or Maguet Rotaflow<sup>¬Æ</sup>.
- An ultrasonic flowmeter.
- Monitor pre- and post-membrane pressures.
- Monitor venous drainage (inlet) pressure.
- No venous reservoir.
- No additional connections to reduce risk of air embolism or bleeding.
- High-flow stop-cocks on the drainage and return lines to allow insertion of a bridge.
</div>
</details>

<details class="med-details">
<summary>Targets on V-V ECMO</summary>
<div class="details-content">

- Protective lung ventilation:
  - FiO<sub>2</sub>  30%, PIP 20‚Äì25, PEEP 10‚Äì15, rate 10.
- Pressure controlled ventilation or BIPAP.
- Target oxygenation  PaO<sub>2</sub>  6‚Äì8kPa adjusted with ECMO circuit flow.
- PaCO<sub>2</sub> 4‚Äì6kPa by adjusting sweep gas flow through oxygenator.
- Unfractionated heparin is infused to maintain an ACT at ~180‚Äì200 seconds or an APTT ratio of 2‚Äì3. These targets depend on the type of ACT machine and local policies.
- Maintain HB at 120‚Äì140g/L.
</div>
</details>

</div>
</details>

</div>
</details>

<details class="med-details">
<summary>Extracorporeal lung support ECLS</summary>
<div class="details-content">

<details class="med-details">
<summary>Novalung¬Æ</summary>
<div class="details-content">

The Novalung¬Æ is a new pumpless extracorporeal membrane which efficiently removed  CO<sub>2</sub>  and also improves oxygenation but less efficiently. Indications are ventilator refractory respiratory failure with predominant hypercapnia and respiratory acidosis. There is a developing role in the management of lung transplant graft dysfunction, ARDS, and pneumonias. Generally the left femoral artery and right femoral vein are cannulated percutaneously.
</div>
</details>

<details class="med-details">
<summary>Contraindications</summary>
<div class="details-content">

- Heparin allergy or heparin-induced thrombocytopenia
- Cardiogenic shock
- Small femoral artery or occlusive vascular disease.
</div>
</details>

<details class="med-details">
<summary>Technical aspects</summary>
<div class="details-content">

- Polymethyl pentene diffusion membrane surface area 1.3m<sup>2</sup>
- Blood flow 0.5‚Äì4.5L/min
- Max oxygen flow 15L/min
- 240mL filling volume
- Max. pressure 200mmHg
- Pressure drop at 2.5L/min is 11mmHg
- Maintain MAP at 70‚Äì90mmHg as the flow is pressure dependant. Administer noradrenalin if necessary
- Heparin-coated system allows minimal anticoagulation
- Infuse heparin to activated clotting time (ACT) 50 ‚Äì70 or APPT 40‚Äì50 seconds
- Check ACT and/or APPT regularly
- Check pulses and clinical perfusion of legs hourly.
</div>
</details>

</div>
</details>

</div>
</details>
